The End of the Needle? A Patent Perspective on Oral TNF-α Modulators
For more than two decades, one class of drugs has quietly transformed the treatment of autoimmune diseases. Therapies that block TNF-α-a key driver of inflammation-have given patients with rheumatoid arthritis,…